Cumberland Pharmaceuticals Inc 8-K, filed May 8, 2020

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

________________________________

FORM 8-K

________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

CUMBERLAND PHARMACEUTICALS INC.

____________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As described below in Item 5.07, on May 5, 2020, at the annual meeting of shareholders of Cumberland Pharmaceuticals Inc. (the “Company”), the shareholders of the Company approved the amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan. Additionally, the shareholders of the Company approved the amendment to the Amended and Restated 2007 Directors’ Incentive Compensation Plan.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 5, 2020, the annual meeting of shareholders of the Company was held in Nashville, Tennessee. The following matters were voted upon and approved by the Company's shareholders:

(1) the election of three (3) Class I Directors and one (1) Class II Director to the Board of Directors;

(2) the advisory vote on executive compensation;

(3) the advisory vote regarding the frequency of future advisory votes on executive compensation;

(4) the approval of an amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan extending such plan through April 21, 2026; and

(5) the approval of an amendment to the Amended and Restated 2007 Directors' Incentive Compensation Plan extending such plan through April 21, 2026.

The voting results were as follows:

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.